A Phase I Study With an Expansion Cohort of the Combinations of Ipilimumab, Nivolumab, and Brentuximab Vedotin in Patients With Relapsed/Refractory Hodgkin Lymphoma

Trial Profile

A Phase I Study With an Expansion Cohort of the Combinations of Ipilimumab, Nivolumab, and Brentuximab Vedotin in Patients With Relapsed/Refractory Hodgkin Lymphoma

Recruiting
Phase of Trial: Phase I

Latest Information Update: 11 Nov 2017

At a glance

  • Drugs Brentuximab vedotin (Primary) ; Ipilimumab (Primary) ; Nivolumab (Primary)
  • Indications Hodgkin's disease
  • Focus Adverse reactions
  • Most Recent Events

    • 06 Nov 2017 Phase of the trial changed from Phase I/II to Phase I; primary endpoint of Complete response (CR) rate deleted hence therapuetic use deleted from trial focus; trial design changed from randomised to no-randomised; Planned number of patients changed from 189 to 63; treatment arm for brentuximab + ipilumumab added.
    • 06 Nov 2017 Planned number of patients changed from 189 to 63.
    • 14 Jul 2017 Phase of the trial changed from Phase I to Phase I/II; primary endpoint of Complete response (CR) rate added hence therapuetic use added to trial focus; trial design changed from non-randomised to randomised; Planned number of patients changed from 70 to 189; treatment arm for brentuximab + ipilumumab removed.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top